Description

TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody
indicated for:

Esophageal Cancer
• in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).
• as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

Gastric Cancer
• in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2- negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1).

Additional information

Brand	TEVIMBRA®
Generic name	Tislelizumab injection
Form	Parenteral
Strength	100mg/10mL
Manufacturer	BeOne
Documents	Either PO or prescription
Storage	Store in a refrigerator at 2 – 8°C.